Abstracts tagged "Immune regulation"

Abstract Number: 1763 • 2013 ACR/ARHP Annual Meeting
IL4-10 Synerkine: A Novel Immunoregulatory Drug To Prevent Immunopathology In Rheumatic Diseases
Sarita Hartgring¹, Cristine Steen-louws², C.E. Hack³, Martin De Smet⁴, Floris Lafeber⁵ and J.A.G. van Roon⁶, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology/Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ³Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: A considerable percentage of patients shows a limited response to biologics targeting one specific inflammatory mediator, largely because of redundancy of these mediators. An…
Abstract Number: 1640 • 2013 ACR/ARHP Annual Meeting
Methotrexate Treatment Affects Effector, But Not Regulatory T Cells in Juvenile Idiopathic Arthritis
Maja Bulatovic Calasan¹, S.J. Vastert², Rianne C. Scholman³, Frederik Verweij³, Mark Klein³, Nico M. Wulffraat⁴, Berent J. Prakken³ and Femke van Wijk³, ¹Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ²Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ³University Medical Center Utrecht, Utrecht, Netherlands, ⁴Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The balance between regulatory (Treg) and effector T cells (Teff) is crucial for immune regulation in juvenile idiopathic arthritis (JIA). How methotrexate (MTX), the…
Abstract Number: 1590 • 2013 ACR/ARHP Annual Meeting
A CD8 T Cell-IFN-γ-IDO Axis Is Required For Mesenchymal Stem Cell Suppression Of Human SLE
Dandan Wang¹, Lin Lu², Xuebing Feng³, Xia Li² and Lingyun Sun³, ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ³Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Stem cell-based regenerative medicine is a promising approach in tissue reconstruction. Mesenchymal stem cells (MSC) show therapeutic effects on human autoimmune diseases including systemic…
Abstract Number: 571 • 2013 ACR/ARHP Annual Meeting
Protective Effect Of Inducible Adeno-Associated Virus Mediated IL-2 Gene Therapy On Tissue Damages In Lupus-Prone Mice
Masayuki Mizui¹, Tomohiro Koga², Linda Lieberman³, Jessica Beltran³, Mark C. Johnson⁴, José C. Crispin², Roland Tisch⁴ and George C. Tsokos⁵, ¹Division of Rheumatology, Department of Medicine,, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: IL-2 plays critical roles not only in immune responses but also in peripheral tolerance. Impairment of IL-2 production has been linked to the development…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].